Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy

by Vandana Singh, Benzinga Editor

June 17, 2021 10:26 AM | 1 min read | Make a Comment

Synlogic Inc SYBX has entered into a research collaboration agreement with Roche Holding AG RHHBY for the discovery of Synthetic Biotic medicine for inflammatory bowel disease (IBD).
Under the terms of the agreement, Synlogic and Roche will collaborate to develop a Synthetic Biotic treatment addressing an undisclosed novel target in IBD.
After the research period, Roche will have the exclusive option to enter a licensing and collaboration agreement to develop further and commercialize the program.
Price Action: SYBX shares are up 2.2% at $4.19 during the premarket session on the last check Thursday.

Posted In: Biotech News Penny Stocks Health Care Contracts General Briefs inflammatory bowel disease

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.